Results 121 to 130 of about 57,075 (302)

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

, 2018
Naoko A Ronquest,1 Tina M Willson,2 Leslie B Montejano,2 Vijay R Nadipelli,1 Bernd A Wollschlaeger3 1Global Health Economics and Outcomes Research, Indivior Inc., Richmond, VA, USA; 2Outcomes Research, Truven Health Analytics®, Part of the IBM Watson
Ronquest NA, Nadipelli VR, Wollschlaeger BA, Montejano LB, Willson TM   +4 more
core  

The association between naloxone distribution, buprenorphine treatment and retention and incident high‐risk opioid prescribing with opioid overdose death in Kentucky, Massachusetts, New York and Ohio, United States: An exploratory community‐level cohort study of data from the HEALing Communities Study

Addiction, EarlyView.
Abstract Aim We evaluated whether community‐level naloxone distribution, medication for opioid use disorder treatment and retention and incident high‐risk opioid prescribing rates were associated with opioid overdose death rates. Design Observational cohort conducted using 2019 to 2023 community‐level data as an exploratory analysis of the HEALing ...
Alexander Y. Walley, Debbie M. Cheng, Nathan Vandergrift, Marc Larochelle, JaNae Holloway, Jennifer L. Brown, Redonna Chandler, Laura C. Fanucchi, Daniel J. Feaster, Patricia R. Freeman, Timothy Hunt, Michelle R. Lofwall, Hannah K. Knudsen, Edward V. Nunes, Emmanuel Oga, Douglas R. Oyler, Jeffrey H. Samet, Jennifer Villani, Sharon L. Walsh, T. John Winhusen   +19 more
wiley   +1 more source

Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids

, 2015
Jon Andsnes Berg,1 Jan Schjøtt,1,2 Kjell O Fossan,1 Bettina Riedel1,21Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital, 2Faculty of Medicine and Dentistry, Department of Clinical Science ...
Fossan KO, Schjøtt J, Berg JA, Riedel B   +3 more
core  

Postoperative Buprenorphine Discontinuation in Continuously Treated Buprenorphine Patients: A Population Cohort Study

, 2021
Sudden discontinuation of buprenorphine in opioid use disorder increases the risk of relapse and overdose. The thesis objective was to understand patient, procedural, opioid treatment-related and health service use factors associated with discontinuing ...
Hauck, Tanya Sabrina
core  

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?

, 2016
Background Buprenorphine is a semi-synthetic opioid used for the treatment of opioid dependence. Opioid use, including buprenorphine, has been increasing in recent years, in the general population and in pregnant women.
Jason Pryor, Shimin Zheng, Kyle, Amy, Singh, Piyuesh, Dankhara, Nilesh, Hagemeier, Nick, Nick Hagemeier, Amy Kyle, Brown, Stacy, Shah, Darshan, Zheng, Shimin, Stacy Brown, Darshan Shah, Piyuesh Singh, Nilesh Dankhara, Pryor, Jason   +15 more
core   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study

Addiction Science & Clinical Practice
Background Buprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals.
J. Luke Engeriser, Thomas Hutch, Crystal L. Smith, Zach Orme, Evan Chavers, Lucinda A. Grande   +5 more
doaj   +1 more source

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method”

, 2016
Robert Hämmig,1 Antje Kemter,2 Johannes Strasser,2 Ulrich von Bardeleben,1 Barbara Gugger,1 Marc Walter,2 Kenneth M Dürsteler,2 Marc Vogel2 1Division of Addiction, University Psychiatric Services Bern, Bern, Switzerland; 2Division of Substance ...
Strasser J, Gugger B, von Bardeleben U, Walter M, Dürsteler KM, Hämmig R, Vogel M, Kemter A   +7 more
core  

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source